InVivoMAb Anti-SARS-CoV-2 RBD
(S6P trimer) Antibody (C144), InVivoMAb 抗SARS-CoV-2RBD (S6P trimer)抗体 (C144)- ￥2588
- abinscience
- France
- VK565050
- 2026年03月03日
- SARS-CoV-2
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 亚型：
IgG1, kappa
- 形态：
Liquid
- 保存条件：
0.01M PBS, pH 7.4.
- 克隆性：
Monoclonal
- 适应物种：
SARS-CoV-2
- 保质期：
1 year
- 抗原来源：
Human
- 目录编号：
VK565050
- 级别：
科研级别
- 库存：
999
- 供应商：
abinscience
- 浓度：
1mg/ml
- 抗体英文名：
InVivoMAb Anti-SARS-CoV-2 RBD (S6P trimer) Antibody (C144)
- 抗体名：
InVivoMAb Anti-SARS-CoV-2 RBD (S6P trimer) Antibody (C144)
- 规格：
100ug
| Product name | InVivoMAb Anti-SARS-CoV-2 RBD (S6P trimer) Antibody (C144) |
|---|---|
| Catalog No. | VK565050 |
| Host species | Human |
| Specificity | \ |
| Conjugation | \ |
| Species reactivity | SARS-CoV-2 |
| Immunogen | \ |
| Form | Liquid |
| Storage buffer | 0.01M PBS, pH 7.4. |
| Purity | >95% as determined by SDS-PAGE. |
| Clonality | Monoclonal |
| Isotype | IgG1, kappa |
| Applications | ELISA, Neutralization |
| Target | Spike glycoprotein, S glycoprotein, E2, Peplomer protein, RBD, Spike protein S1, S, Receptor-Binding Domain, S 6P trimer, SARS-CoV-2 |
| Purification | Protein A/G purified from cell culture supernatant. |
| Accession | P0DTC2 |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
| Background | \ |
| Alternative Names | \ |
| Clone ID | \ |
| Species | \ |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
Abinscience, founded in 2023 and located in the innovation technology center in Strasbourg, France, is the core research reagent brand of ProteoGenix. Focusing on the development and production of life science research reagents, Abinscience takes "Empowering Bioscience Discovery" as its vision, and is committed to providing high-quality and innovative biological reagent products and technical solutions for global researchers.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验中科院高福院士课题组 2020 年发表了哪些重要的研究成果？
：Science 9、Science 后再发 Nature！筛选出又一新冠病毒治疗性单克隆中和抗体DOI: 10.1038/s41586-020-2381-y继之前发表在 Science 上报道筛选出新冠病毒中和抗体后，2020 年 5 月 26 日，高福院士再次联合严景华等人在 Nature 发文：A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2。该研究报告了从 COVID-19 恢复期的患者中分离出两
neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Preprint at bioRxiv 11: Lynch, KL et al. (2020) Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. Preprint
5位院士为代表，超12篇CNS大作，5月新冠研究汇总——全方位围攻新冠病毒，值得收藏
从 8 名 SARS-CoV-2 感染者的单个 B 细胞中分离并鉴定了 206 株 RBD 特异性单克隆抗体，并鉴定出具有抗 SARS-CoV-2 中和活性的抗体，这种中和活性与它们与 ACE2 竞争 RBD 结合的能力有关9。 此外，复旦大学基础医学院应天雷团队在抗新冠抗体药物研发方面也取得了重要的进展，该团队发现了一系列抗新冠全人源纳米抗体，可靶向新冠病毒受体结合区上的五类不同表位。该成果于 5 月 14 日在 Cell Host & Microbe 上发表，题为
技术资料暂无技术资料 索取技术资料
